ANGIOTENSIN-II MAINTAINS, BUT DOES NOT MEDIATE, ISOPROTERENOL-INDUCED CARDIAC-HYPERTROPHY IN RATS

被引:32
|
作者
GOLOMB, E
ABASSI, ZA
CUDA, G
STYLIANOU, M
PANCHAL, VR
TRACHEWSKY, D
KEISER, HR
机构
[1] NHLBI, MOLEC CARDIOL BRANCH, BETHESDA, MD 20892 USA
[2] NHLBI, BIOSTAT RES BRANCH, BETHESDA, MD 20892 USA
关键词
C-FOS; LOSARTAN; POLYMERASE CHAIN REACTION;
D O I
10.1152/ajpheart.1994.267.4.H1496
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats. Iso increased cardiac mass, left ventricular RNA-to-DNA ratio, and the cardiac content of both myosin heavy chain and hydroxyproline in a dose-dependent manner, indicating that Iso-induced cardiac hypertrophy involves growth of both muscle and connective tissue. Cardiac hypertrophy reverted within 11-14 days after cessation of Iso. Propranolol prevented development of Iso-induced cardiac hypertrophy but did not affect the rate of its reversal. The ANG IT receptor blocker losartan (Los) did not significantly decrease the hypertrophic response to Iso. Los injected after cessation of Iso dramatically enhanced the reversal of cardiac hypertrophy, even in rats that received Los with Iso during the induction of Iso-induced cardiac hypertrophy. ANG II, injected continuously at a subpressor dose that did not affect heart weight when given alone, inhibited reversal of cardiac hypertrophy when given after cessation of Iso. Los did not significantly affect the induction of the protooncogene c-fos by Iso. We conclude that endogenous ANG II has a major function in maintaining Iso-induced cardiac hypertrophy but does not mediate its induction. This suggests that different interactive stimuli may be required for development of cardiac hypertrophy, i.e., for initiation and for maintenance.
引用
收藏
页码:H1496 / H1506
页数:11
相关论文
共 50 条
  • [31] EFFECTS OF ACE-INHIBITORS ON CIRCULATING VERSUS CARDIAC ANGIOTENSIN-II IN VOLUME OVERLOAD-INDUCED CARDIAC-HYPERTROPHY IN RATS
    RUZICKA, M
    SKARDA, V
    LEENEN, FHH
    CIRCULATION, 1995, 92 (12) : 3568 - 3573
  • [32] STUDIES ON ADENOSINE-TRIPHOSPHATASE ACTIVITY OF RAT CARDIAC MYOSIN IN ISOPROTERENOL-INDUCED CARDIAC-HYPERTROPHY
    SZABO, J
    NOSZTRAY, K
    SZOOR, A
    ACTA BIOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1977, 28 (04): : 389 - 396
  • [33] Deficiency of iNOS Does Not Prevent Isoproterenol-induced Cardiac Hypertrophy in Mice
    Cha, Hye-Na
    Hong, Geu-Ru
    Kim, Yong-Woon
    Kim, Jong-Yeon
    Dan, Jin-Myoung
    Park, So-Young
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2009, 13 (03): : 153 - 159
  • [34] Requirement of nuclear factor-κB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo
    Freund, C
    Schmidt-Ullrich, R
    Baurand, A
    Dunger, S
    Schneider, W
    Loser, P
    El-Jamali, A
    Dietz, R
    Scheidereit, C
    Bergmann, MW
    CIRCULATION, 2005, 111 (18) : 2319 - 2325
  • [35] EXPERIMENTAL CARDIAC-HYPERTROPHY INDUCED BY ISOPROTERENOL IN RAT
    SZABO, J
    CSAKY, L
    SZEGI, J
    ACTA PHYSIOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1975, 46 (03): : 281 - 285
  • [36] Combinational effect of resveratrol and atorvastatin on isoproterenol-induced cardiac hypertrophy in rats
    Chakraborty, Songjukta
    Pujani, Mukta
    Haque, Syed Ehtaishamul
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2015, 7 (03): : 233 - 238
  • [37] Minocycline Blunts Isoproterenol-Induced Cardiac Hypertrophy
    Russell, Jacob
    Bailey, Chastidy
    Brown, Scott
    DeMarco, Vincent G.
    Mummidi, Srinivas
    Bender, Shawn B.
    Chandrasekar, Bysani
    FASEB JOURNAL, 2022, 36
  • [38] INDUCED CARDIAC-HYPERTROPHY IN RATS
    BOICELLI, CA
    GUARNIERI, C
    TONI, R
    MAGNETIC RESONANCE IN MEDICINE, 1984, 1 (02) : 108 - 109
  • [39] Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system
    Leenen, FHH
    White, R
    Yuan, BX
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (06): : H2410 - H2416
  • [40] EFFECT OF LOSARTAN, AN AT(1) SELECTIVE ANGIOTENSIN-II RECEPTOR ANTAGONIST, ON ISOPROTERENOL-INDUCED CARDIAC ORNITHINE DECARBOXYLASE ACTIVITY
    NAKANO, M
    KANDA, T
    MATSUZAKI, S
    HASEGAWA, S
    MA, HT
    IMAI, S
    SUZUKI, T
    KOBAYASHI, I
    RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, 1995, 88 (01) : 21 - 30